Takeda Pharmaceutical (NYSE:TAK) Insider Giles Richard Platford Sells 55,617 Shares of Company Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Giles Platford sold 55,617 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $20.90, for a total value of $1,162,395.30. Following the sale, the insider owned 270,253 shares of the company’s stock, valued at approximately $5,648,287.70. This trade represents a 17.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Giles Richard Platford also recently made the following trade(s):

• On Monday, August 10th, Giles Platford sold 31,083 shares of Takeda Pharmaceutical stock. The shares were sold at an average price of $17.10, for a total value of $531,519.30.

Takeda Pharmaceutical Price Performance

Shares of NYSE TAK traded up $0.17 during midday trading on Thursday, hitting $21.23. The stock had a trading volume of 4,438,160 shares, compared to its average volume of 3,024,569. The company has a market capitalization of $68.05 billion, a PE ratio of 27.94 and a beta of -0.02. The stock has a 50 day simple moving average of $19.01 and a 200-day simple moving average of $17.62. Takeda Pharmaceutical Co. has a 1 year low of $13.56 and a 1 year high of $21.73. The company has a quick ratio of 0.60, a current ratio of 1.15 and a debt-to-equity ratio of 0.56.

Institutional Investors Weigh In On Takeda Pharmaceutical

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its position in Takeda Pharmaceutical by 14.2% during the first quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock worth $55,358,000 after buying an additional 370,800 shares in the last quarter. Quantinno Capital Management LP grew its holdings in Takeda Pharmaceutical by 20.6% in the 1st quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock valued at $23,878,000 after buying an additional 219,999 shares in the last quarter. Quadrant Capital Group LLC grew its holdings in Takeda Pharmaceutical by 67.8% in the 3rd quarter. Quadrant Capital Group LLC now owns 136,966 shares of the company’s stock valued at $2,537,000 after buying an additional 55,360 shares in the last quarter. Royal Bank of Canada grew its holdings in Takeda Pharmaceutical by 11.0% in the 1st quarter. Royal Bank of Canada now owns 614,851 shares of the company’s stock valued at $11,386,000 after buying an additional 60,725 shares in the last quarter. Finally, Bleakley Financial Group LLC increased its stake in shares of Takeda Pharmaceutical by 19.0% in the 1st quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company’s stock worth $7,993,000 after acquiring an additional 68,844 shares during the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on TAK shares. Weiss Ratings raised Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday. Zacks Research raised shares of Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 30th. Finally, Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes medicines for patients worldwide, with a focus on areas of significant unmet medical need. Its principal therapeutic areas include gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, and medicines for certain blood cancers and rare conditions.